Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

INTERVIEW: Merck Serono's Belén Garijo on pricing, emerging markets and diversity

This article was originally published in Scrip

Executive Summary

You may also be interested in...



GSK, J&J And Roche Speak Up On Women's Equality Day

On Women's Equality Day Scrip spoke to big pharmas, including GlaxoSmithKline PLC, Roche and Johnson & Johnson, about gender equality issues that need highlighting across the life science industry and what their businesses are doing to promote equal opportunities and fair pay.

J.P. Morgan Highlights: Medtech Company Updates For 2022

The annual J.P. Morgan Healthcare Conference saw major medtech companies describe their experiences in 2021 and expectations for 2022 as they continue to cope with COVID-19.

J.P. Morgan Highlights: Major M&A Missing, But Key Takeaways For Year Ahead

The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2022’s meeting of industry leaders, investors and technology creators.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel